› Forums › Mucosal Melanoma Community › ASCO – KIT mutated advanced acral and mucosal melanoma
- This topic is empty.
- Post
-
- June 15, 2011 at 10:05 am
http://abstract.asco.org/AbstView_102_78772.html
A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM).http://abstract.asco.org/AbstView_102_79034.html
http://abstract.asco.org/AbstView_102_78772.html
A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM).http://abstract.asco.org/AbstView_102_79034.html
BRAF, NRAS, and KIT mutational analysis of spindle cell melanoma.http://abstract.asco.org/AbstView_102_79248.html
Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese melanoma patients and their significance: Large, scale analysis of 644 patients.http://abstract.asco.org/AbstView_102_81787.html
Feasability and reliabity of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma.http://abstract.asco.org/AbstView_102_79034.html
BRAF, NRAS, and KIT mutational analysis of spindle cell melanoma.
Tagged: acral, cutaneous melanoma, mucosal melanoma
- You must be logged in to reply to this topic.